New stem cell model to test treatments for neurodegenerative disorders
The team found that astrocytes inhibit growth of precursor cells that become myelin, and speed up the neural network in the brain...
List view / Grid view
The team found that astrocytes inhibit growth of precursor cells that become myelin, and speed up the neural network in the brain...
Cancer cells proliferating in alkalinity should be more vulnerable in acidic environments, so decreasing the pH may result in decreased proliferation...
Many biopharmaceutical companies look to produce biosimilars soon, since the patents on the original mAb expire over the next few years...
A specific haplotype was identified as having the highest risk of development, with another showing the lowest risk...
CMPK2 inhibitors may reduce inflammation, pain and tissue damage in arthritis and gout and in Alzheimer’s may slow loss of cognitive function...
The study showed that patients testing positive for AR-V7 responded better to taxane-based chemotherapy and negative to hormone-targeted therapy...
Drug discovery has always been challenging; today, more so than ever. While there has been success in addressing many diseases, others remain intractable...
How times change. Up to 15 years ago, you would be hard-pressed to find a drug discovery conference with a track dedicated to phenotypic approaches. The underpinning science was called high-content imaging or analysis, being mainly confined to academic drug discovery labs and a handful of pioneers in industry. but…
It may be better to examine the urine and the blood of patients suspected of tumours of the plasma cells...
A new system, pGENMi, could predict genomic features associated with drug responses, by identifying differences in gene expression...
New statistical method, ALFRED, could identify predisposition for cancers by using cancer genome data sets to identify risk variants.
Introducing the Thermo Scientific™ CellInsight™ CX7 LZR High Content Analysis System: the only imaging and analysis platform for advanced performance in screening and analysis.
Sometimes the difference between identifying a partial or super agonist is only the time point at which the binding reaction is measured.
In this issue: urine-derived stem cells offer an innovative platform for drug testing and disease modelling, a paradigm shift in translational stem cell research, and the role of biomaterials in stem cell-based regenerative medicine.
Although readers of Drug Target Review may be more focused upstream of clinical trials in the drug discovery pipeline, the efficacy of clinical trials should also be of interest. Millions of pounds invested in drug discovery in the laboratory could easily go to waste if the clinical trials stage is…